NEuroMuscular Omnicentre (NEMO) is based at the Niguarda Ca’ Granda Hospital in Milan (Italy) and is a highly specialized Center devoted to take care of people affected with neuromuscular diseases, including Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and Muscular Dystrophies. The Centre follows over 1000 neuromuscular patients each year, both day cases and in/outpatients.
NEMO center has 16 rooms for 20 in-patients, day hospital service and multidisciplinary outpatient clinics; two medical gym, one for children and one for adults, are available for in-patient and day hospital rehabilitation. NEMO draws together the expertise of a large team of specialists which perform a multidisciplinary service aimed to cover the full range of needs of neuromuscular patients. The disciplines represented in the team include several professional roles: clinicians neurologist, physiatrist, pulmonologist, nutritionist, psychologists, geneticist, respiratory and motor therapists, speech therapists, dietician, and nurses. NEMO’s team offers comprehensive services in the areas of diagnosis, conventional and experimental treatment protocols (phase II-III clinical trials), rehabilitation, nutrition and pulmonary care and research. During these year other three NEMO Centers were created in Arenzano (Liguria Region), Messina (Sicilia Region) and Roma (Lazio Region).
Christian LunettaPrincipal investigator
Christian Lunetta, MD, is the principal investigator of NEuroMuscular Omnicentre (NEMO).
TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALSRead more
PreLude (Lithium carbonate)
Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.Read more
Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALSRead more
iAdore (Oral edaravone)
Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stressRead more